No Data
CCORF Maintains Atara Biotherapeutics(ATRA.US) With Buy Rating, Cuts Target Price to $13
CCORF analyst John Newman maintains $Atara Biotherapeutics(ATRA.US)$ with a buy rating, and adjusts the target price from $500 to $13.According to TipRanks data, the analyst has a success rate of 39.6
Atara Biotherapeutics Receives Buy Rating Amidst Positive FDA Review and Solid Financial Outlook
Atara Lead Asset Tab-cel Undergoes FDA Priority Review
Atara Biotherapeutics Price Target Cut to $11.00/Share From $12.50 by Goldman Sachs
Atara Biotherapeutics Price Target Cut to $11.00/Share From $12.50 by Goldman
Atara Biotherapeutics Is Maintained at Sell by Goldman Sachs
Atara Biotherapeutics Is Maintained at Sell by Goldman
Goldman Sachs Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $11
Goldman Sachs analyst Tommie Reerink maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Sell and lowers the price target from $12.5 to $11.